LOXO@Lilly

RAMUCIRUMAB

VEGF RECEPTOR-2 ANTAGONIST

The safety and efficacy of the agents for uses under investigation have not been established. Pipeline molecules may not receive regulatory approval and become commercially available for the uses being investigated. The information provided about new molecules being studied is for scientific information exchange purposes only with no commercial intent. For more information on our pipeline, please visit lillyloxooncologypipeline.com.

This document was commissioned by Lilly Medical and is intended to be used by HCPs for medical, scientific, and educational purposes.

RAMUCIRUMAB | MECHANISM OF ACTION[1,2]





References: 1. Adams RH, Alitalo K. *Nat Rev Mol Cell Biol*. 2007;8(6):464-478. **2.** Hicklin DJ, Ellis LM. *J Clin Oncol*. 2005;23(5):1011-1027.

The safety and efficacy of the agents for uses under investigation have not been established. Pipeline molecules may not receive regulatory approval and become commercially available for the uses being investigated. The information provided about new molecules being studied is for scientific information exchange purposes only with no commercial intent. For more information on our pipeline, please visit lillyloxooncologypipeline.com.

This document was commissioned by Lilly Medical and is intended to be used by HCPs for medical, scientific, and educational purposes.

LOXO@Lilly

RAMUCIRUMAB | VEGF RECEPTOR-2 ANTAGONIST

TARGET

Angiogenesis is a tightly regulated, multiple-step process, which results in the formation of new blood vessels from preexisting vasculature and is an important component in the development and progression of malignant disease. Signaling by vascular endothelial growth factor (VEGF) receptor-2 in endothelial cells plays a role in inducing normal and pathologic angiogenesis and is activated by binding of ligands VEGF-A, VEGF-C, and VEGF-D.[1-3]

MOLECULE

Ramucirumab is a human IgG1 monoclonal antibody receptor antagonist that has been shown in vitro to bind to and block the activation of VEGF receptor-2 by preventing the binding of VEGF receptor ligands VEGF-A, VEGF-C, and VEGF-D.[4,5]

CLINICAL DEVELOPMENT

Ramucirumab is being investigated in clinical trials in patients with non-small cell lung cancer or pediatric sarcoma.

References: 1. Adams RH, Alitalo K. *Nat Rev Mol Cell Biol*. 2007;8(6):464-478. **2.** Hicklin DJ, Ellis LM. *J Clin Oncol*. 2005;23(5):1011-1027. **3.** Olsson AK, et al. *Nat Rev Mol Cell Biol*. 2006;7(5):359-371. **4.** Lu D, et al. *J Biol Chem*. 2003;278(44):43496-43507. **5.** Zhu Z, et al. *Leukemia*. 2003;17(3):604-611.

LOXO@Lilly

ACTIVE TRIALS CURRENTLY NOT ENROLLING

[NCT02411448] Lung Cancer
RELAY: A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Participants With EGFR Mutation-Positive Metastatic NSCLC

[NCT04145349] Pediatric Cancer
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

The safety and efficacy of the agents for uses under investigation have not been established. Pipeline molecules may not receive regulatory approval and become commercially available for the uses being investigated. The information provided about new molecules being studied is for scientific information exchange purposes only with no commercial intent. For more information on our pipeline, please visit lillyloxooncologypipeline.com.

This document was commissioned by Lilly Medical and is intended to be used by HCPs for medical, scientific, and educational purposes.

Pipeline information is current through February 6, 2024.

LOXO@Lilly